Technologies, Translational Models, & Biomarker Tools

8.25 - 17.00 EST | 5.25 - 14.00 PST

8:25 am Chair’s Opening Remarks

8:30 am Generated Single-Cell and Spatial Atlases of Autopsy Tissue Samples from Donors who Died of COVID-19


• Hearing the integrated computational analysis uncovering substantial remodeling in the lung, with evidence of multiple paths of failed tissue regeneration
• Learning how viral RNAs were enriched in mononuclear phagocytic and endothelial lung cells, which induced specific host programs
• Exploring a spatial analysis in lung distinguished inflammatory host responses in lung regions with and without viral RNA
• Assessing how the analysis of the other tissue atlases showed transcriptional alterations in multiple cell types in heart tissue from donors with COVID-19

9:00 am Assessing Contributing Molecular Mechanisms of Fibrosis & Identifying Common Threads Across Organs


• Employing single-cell RNA sequencing to define the cell types and mechanisms driving fibrotic remodeling
• Are there common pathways shared by different fibrotic diseases?
• Moving from organ-to-organ into the clinic

9:30 am Speed Networking


This session is the ideal opportunity to establish meaningful business relationships with the brightest minds in the fibrosis field and understand who is also prioritizing, and overcoming challenges within antifibrotic drug development

10:00 am Morning Break

Leveraging Emerging Biomarkers of Fibrotic Disease to Shape Future Clinical Strategy

10:30 am Embracing Alternative Imaging Methodologies: Non-Invasive Imaging to Monitor Detection & Progression of Fibrosis


• Exploring new imaging strategies for fibrosis analysis
• Analyzing recent advances in molecular imaging for early detection, disease staging, and prognostication
• Future imaging approaches in fibrotic disease – advanced AI analytics, multi-omic integration

11:00 am Assessing Available Biomarkers for Predicting Patient Stage & to Inform Clinical Stratification

  • Henrik Landgren Associate Scientific Director, Precision Medicine, Immunology & Fibrosis, AbbVie


• Reviewing clinically relevant biomarkers for identifying patients with fibrosis
• Highlighting the importance of disease staging and patient segmentation for the best clinical outcome
• Reviewing the development of non-invasive biomarkers for disease staging

11:30 am Extracellular Matrix Remodeling is the Common Denominator in all Fibrotic Diseases


  • Fibroblast and the importance in fibro-inflammatory disorders and the quantification thereof
  • Assessing ECM remodeling non-invasively can be used as prognostic and pharmacodynamic biomarkers
  • FACIT collagens: what are they and why are they important?

12:00 pm Networking Lunch

1:00 pm Update from the Prognostic Lung Fibrosis Consortium (PROLIFIC)

  • Peter Schafer Vice President, Translational Medicine, Bristol Myers Squibb


• Unveiling the evidence for the prognostic value of selected blood protein biomarkers in pulmonary fibrosis
• Hearing an update on the development of the multiplex immunoassays
• Exploring future plans for assay qualification, clinical and regulatory applications

1:30 pm The Open Source Imaging Consortium (OSIC) – A Collaborative Model for Imaging Biomarker Discovery in Interstitial Lung Diseases

  • Eric White Senior Clinical Program Lead, ILD, Boehringer Ingelheim


• Introducing a new approach to imaging biomarker discovery
• Highlighting the advantages of collaboration in the imaging biomarker space
• Discussing the opportunities and challenges of creating a global consortium, and next steps

2:00 pm Imaging of Fibrosis

  • Olof Eriksson PET Imaging Director, Associate Professor, Antaros Medical & Uppsala University


  • New advances in clinical non-invasive imaging of fibrosis
  • The potential of PET imaging to detect, diagnose, stage, and study the molecular processes that drive the pathology of fibrosis
  • Use of PET imaging to assist drug development and study drug target engagement

2:15 pm Afternoon Break & Networking

Scaling the Translational Gap: Optimising Next Generation Animal Models & Looking Towards More Humanized Models to Confidently Progress Antifibrotic Drug Candidates into the Clinic

3:15 pm Overcoming the Lack of Relevant Predictive Models: What Does the Industry Need to Define What ‘Good’ Looks Like?


• Exploring key challenges in the translatability of current disease models
• Strategies for developing better predictive models
• Analyzing the shift towards more human-based tissue models
• What are the barriers to accessing disease-viable tissue from humans?
• Balancing efficacy and safety, and considering translatability to other organ systems

3:45 pm From in Vitro to ‘In Matrico’: Human Fibrotic Lung Extracellular Matrix Substrates Increase the Relevance of Cell-Based Lung Fibrosis Models for Antifibrotic Drug Development


  • Discover the IN MATRICO™ Lung Fibrosis Platform, a standardized lung fibrosis model that recapitulates the idiopathic pulmonary fibrosis (IPF) disease environment by incorporating intact human fibrotic lung extracellular matrix thus enabling compound testing assays in disease[1]relevant environments
  • Learn how the IN MATRICO™ Lung Fibrosis Platform provides patient[1]specific clinical data corresponding to the human lung extracellular matrix substrates, bridging the gap to clinical studies by uniquely enabling researchers to ‘bring the patient to the petri dish’
  • Hear how the IN MATRICO™ Lung Fibrosis Platform has been validated with standard-of-care compounds thus offering pharmaceutical companies critical insights, clarity, and confidence to inform and accelerate decision-making in early-stage anti-fibrotic drug development

4:00 pm Establishing Robust and Repeatable Small Animal Models That are More Reflective of the Pathophysiology of Fibrosis


• Reviewing the animal model landscape in the context of fibrosis
• Analyzing data from sequencing to improve understanding of fibroblast populations
• Looking in vitro at cell-cell interactions and utilizing small animal models to understand disease mechanisms

4:30 pm Survey of Preclinical Models of Fibrosis


  • Introduction to Aragen Bioscience as a niche Preclinical Research Services provider
  • Portfolio of preclinical models of fibrosis (in vitro, ex vivo, in vivo)
  • Case studies and connecting factors in different fibrosis models

4:45 pm A Journey Through the Models of Organ Fibrosis From the Simple to the State of the Art & Optimizing Preclinical Models for Novel Antifibrotic Targets


• Evaluating preclinical models of organ fibrosis in the context of angiotensin II type-2 receptor (AT2R) – a novel antifibrotic target
• Tailoring disease models to increase biological relevance
• Hearing the CMO’s perspective on animal models with the end in sight: reflecting human biology and disease pathogenesis

5:15 pm Chair’s Closing Remarks